期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型放射增敏剂Dbait的研究进展 被引量：3

原文传递
导出
摘要 近年来，法国学者报道一种叫Dbait的小分子化合物，该种化合物具有独特的放射增敏机制，体内外研究显示与放射联合具有明显增敏效应，具有良好的应用前景。目前常用的放射增敏剂主要有甘氨双唑钠等。与他们比较Dbait作用机制独特，Dbait分子能靶向性的抑制肿瘤放射后DNA损伤的修复，而甘氨双唑钠是利用其亲电子性选择性增加乏氧细胞毒性。另外Dbait分子的副反应轻微，比SR4233更有利于临床应用。
作者 温林春 章龙珍
机构地区 徐州医学院附属医院放疗科
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2010年第2期142-144,共3页 Chinese Journal of Radiation Oncology
关键词 放射增敏剂 小分子化合物 甘氨双唑钠 SR4233 临床应用 DNA损伤 增敏机制 增敏效应
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献13

  • 1沈瑜,董秀玥.放射增敏剂的研究趋势[J].中华放射肿瘤学杂志,2005,14(6):538-538. 被引量：2
  • 2高远红,杨伟志,徐国镇.SR4233临床研究进展[J].中华放射肿瘤学杂志,2000,9(3):212-214. 被引量：8
  • 3Quanz M,Sun JS,Dutreix M,et al.Small molecule drugs mimicking DNA damage:a new strategy for sensitizing tumors to radiotherapy.Clin Cancer Res,2009,15:1308-1316.
  • 4Quanz M,Chassoux D,Dutreix M,et al.Hyperativation of DNAPK by double-strand break minicking molecules disorganizes DNA damage response.PLOS One,2009,4:6298.
  • 5黄敏,缪泽鸿,丁健.DNA双链断裂损伤修复系统研究进展[J].生理科学进展,2007,38(4):295-300. 被引量：13
  • 6Pang D,Yoo S,Dynan S,et al.Ko proteins join DNA fragments as shown by atomic force microscopy.Cancer Res,1997,57:1412-1415.
  • 7Yoo S,Kimzey A,Dynan W.Photocross-linking of an oriented DNA repair complex.Ku bound at a single DNA end.J Biol Chem,1999,274:20034-20039.
  • 8Walker JR,Corpina RA,Goldberg J.Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair.Nature,2001,412:607-614.
  • 9Nimura Y,Ismail SM,Kurimas L,et al.DNA-PK and ATM are required for radiation enhanced integration.Radiat Res,2002,157:562-567.
  • 10Helleday T,Petermann E,Lundin C,et al.DNA repair pathways as targets for cancer therapy.Nat Rev Cancer,2008,624:162-178.

二级参考文献21

  • 1Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer, 2006, 6 : 789 -802.
  • 2Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem, 1998, 273 : 5858 -5868.
  • 3Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis, 2002, 23 : 687 -696.
  • 4Haber JE. Partners and pathways repairing a double-strand break. Trends Genet, 2000, 16 : 259 -264.
  • 5Sorensen CS, Hansen LT, Dziegielewski J, et al. The cellcycle checkpoint kinase Chkl is required for mammalian homologous recombination repair. Nat Cell Biol, 2005, 7 : 195 - 201.
  • 6Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res, 2005, 65 : 11384 - 11391.
  • 7Bertrand P, Saintigny Y, Lopez BS. p53's double life: transactivation-independent repression of homologous recombination. Trends Genet, 2004, 20 : 235 -243.
  • 8Arias-Lopez C, Lazaro-Trueba I, Kerr P, et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep, 2006, 7 : 219 -224.
  • 9Reddy YV, Ding Q, Lees-Miller SP, et al. Non-homologous end joining requires that the DNA-PK complex undergo an autophosphorylation-dependent rearrangement at DNA ends. J Biol Chem,2004, 279 : 39408 - 39413.
  • 10Block WD, Yu Y, Merkle D, et al. Autophosphorylationdependent remodeling of the DNA-dependent protein kinase catalytic subunit regulates ligation of DNA ends. Nucleic Acids Res, 2004, 32 : 4351 - 4357.

共引文献20

同被引文献57

  • 1Peyromaure M, Debr6 B, Mao K, et al. Management of prostate cancer in China: a multicenter report of 6 institutions [ J ]. J Urol, 2005,174 (5) : 1794 - 1797.
  • 2Ghotra VP, Geldnf AA, Danen EH. Targeted radiosensitization in prostate cancer [ J]. Curt Pharm Des, 2013,19 ( 15 ) : 2819 - 2828.
  • 3laffoul J J, Sarkar FH, Hillman GG. Radiosensitization of prostate cancer by soy isoflavones [ Jl. Curr Cancer Drug Targets, 2007,7 (8) :759 -765.
  • 4Sasaki R, Shirakawa T, Zhang Z J, et al. Additional gene therapy with AdSCMV - p53 enhanced the efficacy of radiotherapy in hu- man prostate cancer cells [J]. Int J Radiat Oncol Biol Phys, 2001,51 (5) :1336 - 1345.
  • 5Cowen D, Salem N, Ashoori F, et al. Prostate cancer radiosensiti- zation in vivo with adenovirus - mediated p53 gene therapy [ J ]. Clin Cancer Res, 2000,6 ( 11 ) :4402 - 4408.
  • 6Watanabe T, Ichikawa A, Saito H, et al. Overexpression of the MDM2 oncogene in leukemia and lym~homa [ J] . Leuk Lympho- ma, 1996,21 (5-6) :391-397.
  • 7Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncop- rotein[ J ] . CellMol Life Sci, 1999, 55 (1) :96 - 107.
  • 8Juven -Gershon T, Oren M. MDM2: the ups and downs[ J]. Mol Meal,1999,5 (2) :71 -83.
  • 9Bianco R, Ciardiello F, Tortora G. Cherhosensitization by anti- sense oligonucleotides targeting MDM2 [ J 1. Curt Cancer Drug Targets ,2005,5(1) :51 -56.
  • 10Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy in-duces growth inhibition and increases efficacy of chemotherapy in prostate cancer [ J ]. Cancer Detect Prey, 2005,29 (2) : 170 - 174.

引证文献3

二级引证文献5

中华放射肿瘤学杂志
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部